

03-30-04



PHA 4254.1 (01258/1/US)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Diane T. Stephenson et al.  
Serial No. 10/743,485  
Filed December 22, 2003

For COMPOSITIONS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND  
SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OR  
PREVENTION OF A VASO-OCCLUSIVE EVENT

March 29, 2004

COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. In accordance with the OG notice of August 5, 2003 partially waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied. Applicant submits herewith copies of the foreign patent documents and literature references.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the date of mailing of this

PHA 4254.1 (01258/1/US)  
PATENT

Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.


Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Kathryn J. Doty', written in a cursive style.

Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

KJD/cms

Express Mail Label No. EV416452256US

PTO/SB/08A			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary) 			Application Number	10/743,485	
			Filing Date	December 22, 2003	
			Confirmation Number		
			First Named Inventor	Diane T. Stephenson	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	5	Attorney Docket No.	PHA 4254.1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	1	5,344,991		Reitz et al.	09/06/1994
	2	5,380,738		Norman et al.	01/10/1995
	3	5,393,790		Reitz et al.	02/28/1995
	4	5,434,178		Talley et al.	07/18/1995
	5	5,466,823		Talley et al.	11/14/1995
	6	5,474,995		Ducharme et al.	12/12/1995
	7	5,510,368		Lau et al.	04/23/1996
	8	5,521,207		Graneto	05/28/1996
	9	5,633,272		Talley et al.	05/27/1997
	10	5,932,598		Talley et al.	08/13/1999
	11	6,034,256		Carter et al.	03/07/2000
	12	6,077,850		Carter et al.	06/20/2000

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/743,485
				Filing Date	December 22,2003
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket No.	PHA 4254.1

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	13	WO	94/13635	A1	Merck Frosst Canada Inc.	06/23/1994	
	14	WO	94/15932	A1	G.D. Searle & Co.	07/21/1994	
	15	WO	94/20480	A1	Merck Frosst Canada Inc.	09/15/1994	
	16	WO	94/26731	A1	Merck Frosst Canada Inc.	11/24/1994	
	17	WO	94/27980	A1	G.D. Searle & Co.	12/08/1994	
	18	WO	95/00501	A2	Merck Frosst Canada Inc.	01/05/1995	
	19	WO	95/15316	A1	G.D. Searle & Co.	06/08/1995	
	20	WO	96/03387	A1	G.D. Searle & Co.	02/08/1996	
	21	WO	96/03388	A1	G.D. Searle & Co.	02/08/1996	
	22	WO	96/06840	A1	Merck Frosst Canada Inc.	03/07/1996	
	23	WO	96/19469	A1	Merck Frosst Canada Inc.	06/27/1996	
	24	WO	96/25405	A1	G.D. Searle & Co.	08/22/1996	
	25	WO	98/03484	A1	Merck Frosst Canada Inc.	01/29/1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/743,485
				Filing Date	December 22,2003
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	3	of	5	Attorney Docket No.	PHA 4254.1

<b>OTHER ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	26	ANDRE-PETERSSON et al., "Adaptive Behavior in Stressful Situations and Stroke Incidence in Hypertensive Men", Stroke, 2001, 32: 1712-1720	
	27	BOUCHARD JF, et al., "Mechanisms of Protection Afforded by Cyclooxygenase Inhibitors to Endothelial Function Against Ischemic Injury in Rat Isolated Hearts", Journal of Cardiovascular Pharmacology, 1999 Nov.; 34(5): 755-63	
	28	BYMASTER et al., "Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat", Neuropsychopharmacology, 2002, 27(5): 699-711	
	29	CHALDAKOV, "Proposal for Clinical Trials using Anti-inflammatory Drugs in the Therapy of Angina Pectoris, Myocardial Infarction and Coronary Restenosis after Angioplasty and Bypass Grafting" Medical Hypotheses, 1992, 37: 74-75	
	30	Fibrinolytic Therapy Trialists' "Indications for Fibrinolytic Therapy in Suspected Acute Myocardial Infarction", Lancet, 1994, 343: 311-22	
	31	GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase", Biochem Journal, 1995, 305: 479-84	
	32	GORELICK PB, "Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy", Stroke, 2002, 33:862-875	
	33	GRINSTEAD et al., "Amiprilose in the Prevention of Restenosis After Coronary Intervention in a Swine Model", 1993, Coron Artery Dis, 4: 277-281	
	34	HUANG et al., "Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation", European Journal of Pharmacology, 1992, 221: 381-384	
	35	ISHIWATA et al., "Inhibition of Neointima Formation by Tranilast in Pig Coronary Arteries After Balloon Angioplasty and Stent Implantation", Journal of the American College of Cardiology, 2000, 35: 1331-1337	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/743,485
				Filing Date	December 22,2003
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	4	of	5	Attorney Docket No.	PHA 4254.1

	36	JORGE et al., "Mortality and Poststroke Depression: A Placebo-Controlled Trial of Antidepressants", American Journal of Psychiatry, 2003, 160(10): 1823-1829	
	37	LEE et al., "Prospective Randomized Trial of Corticosteroids for the Prevention of Restenosis After Intracoronary Stent Implantation", American Heart Journal, 1999, 138: 60-63	
	38	LOUBINOUX I, et al., "A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: double-blind, placebo-controlled, fMRI study in healthy subjects", Neuroimage, 2002 Jan.; 15(1): 26-36	
	39	METAIS C, et al., "Serotonin-Induced Coronary Contraction Increases After Blood Cardioplegia-Reperfusion", Circulation, 1999 Nov. 9; 100(19 Suppl): II328-34	
	40	METAIS C, et al., "Serotonin-induced human coronary microvascular contraction during acute myocardial ischemia is blocked by COX-2 inhibition", Basic Research in Cardiolgy, 2001 Feb.; 96(1): 59-67	
	41	NAPOLI et al., "Inflammation, Hemostatic Markers, and Antithrombotic Agents in Relation to Long-Term Risk of New Cardiovascular Events in First-Ever Ischemic Stroke Patients", Stroke, 2002, 33: 1763-1771	
	42	PARIKH et al., "The Impact of Poststroke Depression on Recovery in Activities of Daily Living Over a 2-Year Follow-up" Archives of Neurology, 1990, 47: 785-789	
	43	PERRY et al., "Selective Serotonin Reuptak Inhibitors and the Treatment of Affective Illness", Clinical Psychopharmacology Seminar, 1996	
	44	POLLOCK BG, et al., "Evaluation of Platelet Activation in Depressed Patients with Ischemic Heart Disease After Paroxetine or Nortriptyline Treatment" J Clin Psychopharmacol, 2000; 20(2): 137-140	
	45	RAB et al., "Coronary Aneurysms After Stent Placement: A Suggestion of Altered Vessel Wall Healing in the Presence of Anti-inflammatory Agents" Journal of the American College of Cardiology., 1991, 18: 1524-1528	
	46	RIDKER PM, et al., "Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men", New England Journal of Medicine., 1997; 336(14): 973-979	
	47	SATO K, et al., "Increased Pulmonary Vascular Contraction to Serotonin After Cardiopulmonary Bypass", Journal of Surgical Research., 2000 May 15; 90(2): 138-43	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/743,485
				Filing Date	December 22,2003
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	5	of	5	Attorney Docket No.	PHA 4254.1

	48	SEREBRUANY VL, et al., "Platelet Inhibition by Sertraline and N-Desmethylertraline", Pharmacological Research, 2001 May; 43(5): 453-62	
	49	SINGHAL AB, et al., "Cerebral Vasoconstriction and Stroke After Use of Serotonergic Drugs", Neurology, 2002 Jan 8; 58(1): 130-3	
	50	SKOP BP et al., "Potential Vascular and Bleeding Complications of Treatment with Selective Serotonin Reuptake Inhibitors", Psychosomatics, 1996, Jan.-Feb.; 37(1): 12-16	
	51	STRECKER et al., "Effect on Intimal Hyperplasia of Dexamethasone Released from Coated Metal Stents Compared with Non-Coated Stents in Canine Femoral Arteries", Cardiovascular and Interventional Radiology, 1998, 21: 487-496	
	52	SUGO et al., "Social Stress Exacerbates Focal Cerebral Ischemia in Mice", Stroke, 2002, 33: 1660-1664	
	53	VALERO et al., "Intramural Injection of Biodegradable Microspheres as a Local Drug-Delivery System to Inhibit Neointimal Thickening in a Rabbit Model of Balloon Angioplasty" Journal of Cardiovascular Pharmacology, 1998, 31: 513-519	
	54	VILA et al., "Proinflammatory Cytokines and Early Neurological Worsening in Ischemic Stroke", Stroke, 2000, 31:2325-2329	
	55	YUSUF, et al., "Intravenous and Intracoronary Fibrinolytic Therapy in Acute Myocardial infarction: Overview of Results on Mortality, Reinfarction and Side-Effects from 33 Randomized Controlled Trials", European Heart Journal, 1985, 6:556-85	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.